In the study of Butterfield et al., a clinical trial [NCT01622933] evaluated the ability of an antigen-engineered DC vaccine to induce a polyclonal CD8+ and CD4+ T-cell response against three common melanoma antigens. The gene discussed is CD8A; the disease is melanoma.